Brief: Adial Pharmaceuticals Achieves Important Milestone of First Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
05/06/2024 13:36
June 5 (Reuters) - Adial Pharmaceuticals Inc ADIL.O :
* ADIAL PHARMACEUTICALS- ACHIEVES IMPORTANT MILESTONE OF
FIRST
PATIENT DOSED IN PHARMACOKINETICS STUDY OF AD04 FOR TREATMENT OF
ALCOHOL USE DISORDER
* ADIAL PHARMACEUTICALS INC - TOPLINE RESULTS EXPECTED IN
EARLY Q4
2024
Source text for Eikon: ID:nGNXmgVxH
Further company coverage: ADIL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)